

+ + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + +

Nevada PEBP

Q3 FY2026

Prepared by Client Analytics

Mathew Gehrin (mgehrin@express-scripts.com)

5/28/2026

**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q3 FY26 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

| CDHP Overall Trend | | % Change |
|---|---------|----------------------|
| Current Period - Plan Cost Net PMPM | | \$98.22 |
| Utilization | \$0.61 | 0.8% |
| Unit Cost | \$13.38 | 17.1% |
| Member Share | \$5.93 | 7.6% |
| Total Change in Plan Cost Net PMPM | | \$19.92 25.4% |
| Previous Period - Plan Cost Net PMPM | | \$78.31 |

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$864k (37.3%) to current \$3.2M.
 - Plan Cost Net PMPM ↑ \$4.57 (40.8%) to current \$15.77.
 - Patient Count ↑ 19 to current count of 252.
 - Adjusted Rx's ↑ 118 to current count of 1,862.
- **Notable Drug Changes within Indication:**
 - **Rinvoq:**
 - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$115k (44.9%) to current \$370k.
 - Plan Cost Net PMPM ↑ \$.60 (48.6%) to current \$1.84.
 - Patient Count ↑ 3 to current count of 15.
 - Adjusted Rx's ↑ 19 to current count of 99.
 - **Ilaris:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$320k.
 - Plan Cost Net PMPM: New, current \$1.59.
 - Patient Count: New, current count of 3.
 - Adjusted Rx's: New, current count of 24.

- **Bimzelx Autoinjector:**
 - Previously ranked 11th, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net ↑ \$86k (104.1%) to current \$169k.
 - Plan Cost Net PMPM ↑ \$.44 (109.3%) to current \$.84.
 - Patient Count ↑ 2 to current count of 5.
 - Adjusted Rxs ↑ 19 to current count of 26.
- **Pulmonary Hypertension:** Previously ranked 13th, currently ranked 8th by Plan Cost Net.
 - Plan Cost Net ↑ \$677k (238.6%) to current \$961k.
 - Plan Cost Net PMPM ↑ \$3.39 (247.2%) to current \$4.77.
 - Patient Count ↑ 3 to current count of 6.
 - Adjusted Rxs ↑ 53 to current count of 90.
- **Notable Drug Changes within Indication:**
 - **Tyvaso DPI:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current 427k.
 - Plan Cost Net PMPM: New, current \$2.12.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 21.
 - **Opsynvi:**
 - New, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net: New, current 164k.
 - Plan Cost Net PMPM: New, current \$.81.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 18.
 - **Winrevair:**
 - New, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net: New, current 75k.
 - Plan Cost Net PMPM: New, current \$.37.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 5.
- **Ophthalmic Conditions:** Previous ranked 26th, currently ranked 12th by Plan Cost Net.
 - Plan Cost Net ↑ \$455k (349.3%) to current \$586k.
 - Plan Cost Net PMPM ↑ \$2.27 (360.8%) to current \$2.91.
 - Patient Count ↓ 29 to current count of 261.
 - Adjusted Rxs ↓ 84 to current count of 630.
- **Notable Drug Changes within Indication:**
 - **Tepezza:**

- New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$430k.
 - Plan Cost Net PMPM: New, current \$2.13.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 8.
- **Other drug changes in this indication were not notable.**
- **Enzyme Deficiencies:** Previously ranked 47th, currently ranked 13th by Plan Cost Net.
 - Plan Cost Net ↑ \$380k (1,582.6%) to current \$404k.
 - Plan Cost Net PMPM ↑ \$1.88 (1,625.5%) to current \$4.10.
 - Patient Count ↑ 3 to current count of 4.
 - Adjusted Rxs ↑ 15 to current count of 20.
- **Notable Drug Changes within Indication:**
 - **Fabrazyme:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$327k.
 - Plan Cost Net PMPM: New, current \$1.62.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 9.
 - **Sucraid:**
 - Previously ranked 1st, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$48k (200.8%) to current \$72k.
 - Plan Cost Net PMPM ↑ \$.24 (208.5%) to current \$.36.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 4 to current count of 9.

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer in Plan Cost Net PMPM but has a higher trend.
- Peer experienced Plan Cost Net PMPM of \$108.81 compared to CDHP PEBP of \$98.22.
- Peer experienced Trend of 16.8%, compared to CDHP PEBP Trend of 25.4%

EPO Overall Trend Summaries:

| EPO Overall Trend | | % Change |
|---|----------------|-----------------|
| Current Period - Plan Cost Net PMPM | | \$200.47 |
| Utilization | \$9.29 | 5.3% |
| Unit Cost | \$6.43 | 3.6% |
| Member Share | \$8.15 | 4.6% |
| Total Change in Plan Cost Net PMPM | \$23.87 | 13.5% |
| Previous Period - Plan Cost Net PMPM | | \$176.60 |

Top moving indications and most notable drug changes within the indications are as follows:

- **Gout:** Previous ranked 14th, currently ranked 53rd by Plan Cost Net.
 - Plan Cost Net ↓ \$172k (-98.2%) to current \$3k.
 - Plan Cost Net PMPM ↓ \$3.65 (-97.9%) to current \$.08.
 - Patient Count ↓ 17 to current count of 113.
 - Adjusted Rx's ↓ 45 to current count of 695.
- **Notable Drug Changes within Indication:**
 - **Krystexxa:**
 - Previously ranked 1st, not currently utilized.
 - Plan Cost Net: Previous, \$167k.
 - Plan Cost Net PMPM: Previous, \$3.56.
 - Patient Count: Previous count of 2.
 - Adjusted Rx's: Previous count of 4.
 - **Other drug changes in this indication were not notable.**
- **Multiple Sclerosis:** Previous ranked 10th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$142k (57.1%) to current \$390k.
 - Plan Cost Net PMPM ↑ \$4.36 (82.3%) to current \$9.65.
 - Patient Count ↑ 1 to current count of 8.
 - Adjusted Rx's ↑ 4 to current count of 63.
- **Notable Drug Changes within Indication:**
 - **Mavenclad:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$86k.
 - Plan Cost Net PMPM: New, current \$2.13.
 - Patient Count: New, current count of 1.
 - Adjusted Rx's: New, current count of 1.

- **Kesimpta Pen:**
 - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$86k (114.1%) to current \$161k.
 - Plan Cost Net PMPM ↑ \$2.39 (148.5%) to current \$4.00.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↑ 9 to current count of 20.

- **Endocrine Disorders:** Previously ranked 12th, currently ranked 24th by Plan Cost Net.
 - Plan Cost Net ↓ \$125k (-60.0%) to current \$83k.
 - Plan Cost Net PMPM ↓ \$2.37 (-53.5%) to current \$2.06.
 - Patient Count ↓ 8 to current count of 23.
 - Adjusted Rxs ↓ 35 to current count of 141.

- **Notable Drug Changes within Indication:**
 - **Korlym:**
 - No Longer utilized, previously ranked 1st by Plan Cost Net.
 - Plan Cost Net: Previously \$80k.
 - Plan Cost Net PMPM: Previously \$1.71.
 - Patient Count: Previous count of 2.
 - Adjusted Rxs: Previous count of 2.

 - **Supprelin LA:**
 - No Longer utilized, previously ranked 3rd by Plan Cost Net.
 - Plan Cost Net: Previously \$49k.
 - Plan Cost Net PMPM: Previously \$1.04.
 - Patient Count: Previous count of 1.
 - Adjusted Rxs: Previous count of 12.

 - **Other drug changes in this indication were not notable.**

- **Muscle Relaxant:** Previously ranked 57th, currently ranked 19th by Plan Cost Net.
 - Plan Cost Net ↑ \$117k (2,920.8%) to current \$118k.
 - Plan Cost Net PMPM ↑ \$2.92 (3,407.0%) to current \$3.00.
 - Patient Count: Remains at 404.
 - Adjusted Rxs ↑ 9 to current count of 1,391.

- **Notable Drug Changes within Indication:**
 - **Skyclarys:**
 - New, Currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$118k.
 - Plan Cost Net PMPM: New, current \$2.92.
 - Patient Count: New, current count of 1.

- Adjusted Rxs: New, current count of 4.
- **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO in Plan Cost Net PMPM, however PEBP EPO plan has a significantly lower trend.
- Peer experienced Plan Cost Net PMPM of \$172.15 compared to PEBP EPO of \$200.47
- Peer experienced Trend of 21.5%, compared to PEBP EPO of 13.5%

PPO Overall Trend Summaries:

| PPO Overall Trend | | % Change |
|--|---------|-----------------|
| Current Period - Plan Cost Net PMPM | | \$127.65 |
| Utilization | \$5.83 | 5.6% |
| Unit Cost | \$12.73 | 12.3% |
| Member Share | \$5.32 | 5.1% |
| Total Change in Plan Cost Net PMPM | | \$23.87 |
| | | 23.0% |

Previous Period - Plan Cost Net PMPM **\$103.77**

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previously ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$1.7M (53.4%) to current \$4.8M.
 - Plan Cost Net PMPM ↑ \$5.80 (39.2%) to current \$20.62.
 - Patient Count ↑ 53 to current count of 387.
 - Adjusted Rxs ↑ 446 to current count of 2,855.
- **Notable Drug Changes within Indication:**
 - **Rinvoq:**
 - Previously ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$194k (44.5%) to current \$631k.
 - Plan Cost Net PMPM ↑ \$.65 (31.1%) to current \$2.74.
 - Patient Count ↑ 4 to current count of 23.
 - Adjusted Rxs ↑ 38 to current count of 172.
 - **Skyrizi On-Body:**
 - Previously ranked 14th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$153k (249.0%) to current \$214k.
 - Plan Cost Net PMPM ↑ \$.64 (216.7%) to current \$.93.

- Patient Count ↑ 5 to current count of 7.
- Adjusted Rxs ↑ 32 to current count of 42.
- **Bimzelx Autoinjector:**
 - Previously ranked 23rd, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net ↑ \$151k (471.9%) to current \$183k.
 - Plan Cost Net PMPM ↑ \$.64 (418.9%) to current \$.79.
 - Patient Count ↑ 3 to current count of 52.
 - Adjusted Rxs ↑ 18 to current count of 24.
- **Adalimumab-ADB(MCF) Pen (Humira Biosimilar):**
 - New, currently ranked 7th by Plan Cost Net.
 - Plan Cost Net: New, current \$176k.
 - Plan Cost Net PMPM: New, current \$.77.
 - Patient Count: New, current count of 31.
 - Adjusted Rxs: New, current count of 171.
- **Enzyme Deficiencies:** Previously ranked 4th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$827k (82.6%) to current \$1.8M.
 - Plan Cost Net PMPM ↑ \$3.14 (65.7%) to current \$7.93.
 - Patient Count ↓ 1 to current count of 10.
 - Adjusted Rxs ↑ 41 to current count of 79.
- **Notable Drug Changes within Indication:**
 - **Yorvipath:**
 - Previously ranked 6th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$834k (1,254.2%) to current \$901k.
 - Plan Cost Net PMPM ↑ \$3.59 (1,128.6%) to current \$3.91.
 - Patient Count ↑ 5 to current count of 6.
 - Adjusted Rxs ↑ 43 to current count of 46.
 - **Imcivree:**
 - New, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net: New, current \$272k.
 - Plan Cost Net PMPM: New, current \$1.18.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 9.
 - **Nexvazyme:**
 - No Longer utilized, previously ranked 2nd by Plan Cost Net.
 - Plan Cost Net: Previously \$151k.
 - Plan Cost Net PMPM: Previously \$.72.
 - Patient Count: Previous count of 1.
 - Adjusted Rxs: Previous count of 2.
 - **Galafold:**
 - No Longer utilized, previously ranked 3rd by Plan Cost Net.
 - Plan Cost Net: Previously \$119k.

- Plan Cost Net PMPM: Previously \$.57.
 - Patient Count: Previous count of 1.
 - Adjusted Rxs: Previous count of 4.
- **Diabetes:** Previously ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$753k (26.5%) to current \$3.6M.
 - Plan Cost Net PMPM ↑ \$2.00 (14.7%) to current \$15.61.
 - Patient Count ↑ 190 to current count of 2068.
 - Adjusted Rxs ↑ 1,717 to current count of 24,601.
- **Notable Drug Changes within Indication:**
 - **Mounjaro:**
 - Previously ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$682k (71.6%) to current \$1.6M.
 - Plan Cost Net PMPM ↑ \$2.54 (55.7%) to current \$7.10.
 - Patient Count ↑ 230 to current count of 619.
 - Adjusted Rxs ↑ 1,672 to current count of 4,488.
 - **Other drug changes in this indication were not notable.**
- **Cancer:** Previously ranked 3rd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$616k (35.1%) to current \$2.4Mk.
 - Plan Cost Net PMPM ↑ \$1.89 (22.5%) to current \$10.30.
 - Patient Count ↑ 36 to current count of 237.
 - Adjusted Rxs ↑ 208 to current count of 1,449.
- **Notable Drug Changes within Indication:**
 - **Idihifa:**
 - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$107k (48.8%) to current \$327k.
 - Plan Cost Net PMPM ↑ \$.37 (35.0%) to current \$1.42.
 - Patient Count remains at 2.
 - Adjusted Rxs ↑ 3 to current count of 10.
 - **Tibsovo:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$259k.
 - Plan Cost Net PMPM: New, current \$1.12.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 8.
 - **Kisqali:**
 - Previously ranked 20th, currently ranked 5th by Plan Cost Net.

- Plan Cost Net ↑ \$218k (1,157.8%) to current \$237k.
- Plan Cost Net PMPM ↑ \$.94 (1,041.2%) to current \$1.03.
- Patient Count ↑ 1 to current count of 2.
- Adjusted Rxs ↑ 16 to current count of 20.

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer in Plan Cost Net PMPM, however PEBP PPO plan has a slightly higher trend.
- PEBP PPO experienced Plan Cost Net PMPM of \$127.65 compared to peer of \$172.15.
- Peer experienced Trend of 21.5%, compared to PEBP PPO of 23.0%.

| Total Overall Trend | | % Change |
|--------------------------------------|---------|---------------|
| Current Period - Plan Cost Net PMPM | | \$121.32 |
| Utilization | \$2.78 | 2.8% |
| Unit Cost | \$12.75 | 12.8% |
| Member Share | \$6.01 | 6.0% |
| Total Change in Plan Cost Net PMPM | | \$21.54 21.6% |
| Previous Period - Plan Cost Net PMPM | | \$99.78 |

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 16.9% in Specialty patients. This resulted in a 21.2% increase in Specialty Days of Therapy.

Trend was mitigated by increased rebates of 5.0%. Which reduced combine Unit Cost Trend to 12.8%.

Member Cost contributed to Trend on both Specialty and Non-Specialty drugs. This is due to increased Utilization on Specialty drugs and Drug Mix on Non-Specialty drugs. Primarily driven by utilization of more expensive drugs (exchanging utilization of a brand drug for a more expensive brand drug).

Key Statistics:

| Nevada PEBP Total | | | |
|-------------------------------------|--------------|--------------|--------|
| Description | Q3 FY26 | Q3 FY25 | Change |
| Average Members per Month | 52,503 | 51,421 | 2.1% |
| Number of Unique patients | 37,513 | 36,778 | 2.0% |
| Members Utilizing the Benefit | 71.4% | 71.5% | -0.1 |
| Gross Cost/Adjusted Rx | \$162.97 | \$148.86 | 9.5% |
| Plan Spend | \$86,639,471 | \$74,080,635 | 17.0% |
| Rebates (estimated) | \$29,313,774 | \$27,905,130 | 5.0% |
| Plan Cost Net | \$57,325,697 | \$46,175,506 | 24.1% |
| Plan Cost Net PMPM | \$121.32 | \$99.78 | 21.6% |
| Non-Specialty Plan Cost Net PMPM | \$84.04 | \$79.19 | 6.1% |
| Specialty Plan Cost Net PMPM | \$99.32 | \$80.88 | 22.8% |
| Generic Fill Rate | 86.8% | 86.7% | 0.2 |
| 90 Day Utilization | 59.6% | 59.9% | -0.3 |
| Retail - Maintenance 90 Utilization | 32.2% | 29.5% | 2.7 |
| Home Delivery Utilization | 26.3% | 29.6% | -3.3 |
| Member Cost Net % | 15.8% | 18.0% | -2.1 |

END OF REPORT